Close
Achema middle east
swop processing & packaging

Predictive oncology to launch AI drug discovery platform for Covid-19

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

ACHEMA 2027: Global Forum for Pharma and Life Sciences

ACHEMA 2027 sets an even stronger focus on innovations...

Amcor to showcase responsible and patient-centric packaging innovations at CPHI Frankfurt 2025

User-friendly solutions designed to enhance convenience, performance and patient...

Kadans Science Partner secures one of the most significant deals in Glasgow of H1 2025

Chemify scales up operations at Health Innovation Hub Digital...

Predictive Oncology has announced plans to launch an artificial intelligence (AI) technology platform for vaccine and drug development under an operating agreement with Soluble Therapeutics.

The company is focussed on coronaviruses and acute respiratory syndromes, including Covid-19, MERS and SARS.

Predictive Oncology also signed a letter of intent with InventaBioTech to buy Soluble Therapeutics, its assets and HSC Technology.

Soluble Therapeutics’ computer system uses HSC technology and its six machines to run more than 12,000 computer simulations per machine to produce new diagnostics, vaccines and drugs.

The HSC technology showed efficacy with new and existing vaccine and drug programmes, said the company.

By combining this technology with Predictive Oncology’s predictive modelling platform, the company anticipates developing a new AI discovery platform.

Predictive Oncology CEO Carl Schwartz said: “Soluble has six customised machines in its facilities that can help identify the best solutions for vaccines, proteins or antibodies being developed to help fight the COVID-19 contagion.

“Through this operating partnership and acquisition, we are ready to assist in the development of viable treatment options that use biological, complex ingredients and formulations to speed up the pre-clinical and clinical development of treatments.”

Subject to customary closing conditions, the acquisition of Soluble Therapeutics is set to complete in the second quarter of this year.

Latest stories

Related stories

ACHEMA 2027: Global Forum for Pharma and Life Sciences

ACHEMA 2027 sets an even stronger focus on innovations...

Amcor to showcase responsible and patient-centric packaging innovations at CPHI Frankfurt 2025

User-friendly solutions designed to enhance convenience, performance and patient...

Kadans Science Partner secures one of the most significant deals in Glasgow of H1 2025

Chemify scales up operations at Health Innovation Hub Digital...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »